// App-Quantinova.ai

: Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediate-risk non–muscle-invasive bladder cancer (IR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 3 interim analysis.

Researchers

Presenter

  • Siamak Daneshmand

Principal Investigators

  • Renata Zaucha

  • Benjamin Adam Gartrell

  • Yair Lotan

  • Syed A. Hussain

  • Eugene K. Lee

  • Giuseppe Procopio

  • Fernando Galanternik

  • Vahid Naini

  • Jenna Carcione

  • Spyros Triantos

  • Mahadi Baig

  • Jodi K. Maranchie

Medical Centers

  • University of Kansas Health System, Kansas City, KS

  • University of Southern California, Los Angeles, CA

  • University of Pittsburgh Medical Center, Pittsburgh, PA

  • Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Centro de Educacion Medica e Investigaciones Clinicas (CEMIC), Buenos Aires, Argentina

  • UTSouthwestern Medical Center, Dallas, TX

  • University of Sheffield, Sheffield, United Kingdom

  • Janssen Research and Development, LLC, Spring House, PA

  • Medical University of Gdansk, Gdansk, Poland

  • Janssen Research & Development, San Diego, CA

  • Montefiore Medical Center, New York, NY

Locations

  • Argentina

  • United Kingdom

  • Italy

  • Poland

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • Fibroblast growth factor receptor 3

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT04172675

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved